JP2018524352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524352A5 JP2018524352A5 JP2017568376A JP2017568376A JP2018524352A5 JP 2018524352 A5 JP2018524352 A5 JP 2018524352A5 JP 2017568376 A JP2017568376 A JP 2017568376A JP 2017568376 A JP2017568376 A JP 2017568376A JP 2018524352 A5 JP2018524352 A5 JP 2018524352A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- complex according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000005647 linker group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 238000010276 construction Methods 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 8
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 8
- 239000005977 Ethylene Substances 0.000 claims description 8
- 125000006244 carboxylic acid protecting group Chemical group 0.000 claims description 8
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 238000011503 in vivo imaging Methods 0.000 claims description 4
- 150000002739 metals Chemical class 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000003384 imaging method Methods 0.000 description 20
- 238000012636 positron electron tomography Methods 0.000 description 13
- 239000010949 copper Substances 0.000 description 12
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 10
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 10
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 239000002738 chelating agent Substances 0.000 description 9
- 238000012879 PET imaging Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000012217 radiopharmaceutical Substances 0.000 description 6
- 229940121896 radiopharmaceutical Drugs 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 0 *C(NC(P(*)(O)=O)P(O)(O*)=O)=O Chemical compound *C(NC(P(*)(O)=O)P(O)(O*)=O)=O 0.000 description 5
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 5
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 description 5
- 229910052733 gallium Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940122361 Bisphosphonate Drugs 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013170 computed tomography imaging Methods 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 3
- 230000002799 radiopharmaceutical effect Effects 0.000 description 3
- XBJPSVQFCQFGDC-WSCOIBMGSA-K 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate gallium-68(3+) Chemical compound [68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O XBJPSVQFCQFGDC-WSCOIBMGSA-K 0.000 description 2
- 206010027452 Metastases to bone Diseases 0.000 description 2
- ACHQFNGCBWWVRR-UHFFFAOYSA-N NOPO Chemical compound NOPO ACHQFNGCBWWVRR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 150000002258 gallium Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012831 peritoneal equilibrium test Methods 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- PUZPDOWCWNUUKD-ULWFUOSBSA-M sodium;fluorine-18(1-) Chemical compound [18F-].[Na+] PUZPDOWCWNUUKD-ULWFUOSBSA-M 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 1
- ZQXIMYREBUZLPM-UHFFFAOYSA-N 1-aminoethanethiol Chemical compound CC(N)S ZQXIMYREBUZLPM-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- RZHKDBRREKOZEW-AAXZNHDCSA-N 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl] Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C1=CC=CC=C1 RZHKDBRREKOZEW-AAXZNHDCSA-N 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 108010004081 68Ga-NODAGA-RGD Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229940120146 EDTMP Drugs 0.000 description 1
- 108700038672 Edotreotide Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- OUJRYYLEOPKIOL-ZANHISICSA-N OC(CN(CCN(CC(O)=O)Cc1cc(CCC(NC(P(O)(O)=O)P(O)(O)=O)=O)ccc1O)Cc(cc(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(NC(C1)(C1C(O)=O)C(O)=O)=O)=O)=O)cc1)c1O)=O Chemical compound OC(CN(CCN(CC(O)=O)Cc1cc(CCC(NC(P(O)(O)=O)P(O)(O)=O)=O)ccc1O)Cc(cc(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(NC(C1)(C1C(O)=O)C(O)=O)=O)=O)=O)cc1)c1O)=O OUJRYYLEOPKIOL-ZANHISICSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical class CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IUPNVOAUFBLQME-SGNQUONSSA-L dioxidanium;dioxido-oxo-(phosphonatomethyl)-$l^{5}-phosphane;technetium-99(4+) Chemical compound [OH3+].[OH3+].[99Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O IUPNVOAUFBLQME-SGNQUONSSA-L 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- RJMMFJHMVBOLGY-UHFFFAOYSA-N indium(3+) Chemical compound [In+3] RJMMFJHMVBOLGY-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 150000003746 yttrium Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189652P | 2015-07-07 | 2015-07-07 | |
| US62/189,652 | 2015-07-07 | ||
| US201662320296P | 2016-04-08 | 2016-04-08 | |
| US62/320,296 | 2016-04-08 | ||
| PCT/US2016/041040 WO2017007790A1 (en) | 2015-07-07 | 2016-07-06 | Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524352A JP2018524352A (ja) | 2018-08-30 |
| JP2018524352A5 true JP2018524352A5 (enExample) | 2019-07-25 |
| JP6792875B2 JP6792875B2 (ja) | 2020-12-02 |
Family
ID=57685907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568376A Active JP6792875B2 (ja) | 2015-07-07 | 2016-07-06 | Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10253052B2 (enExample) |
| EP (1) | EP3319643B1 (enExample) |
| JP (1) | JP6792875B2 (enExample) |
| KR (1) | KR102651945B1 (enExample) |
| CN (1) | CN107847618B (enExample) |
| AU (1) | AU2016289474C1 (enExample) |
| CA (1) | CA2991498A1 (enExample) |
| DK (1) | DK3319643T3 (enExample) |
| EA (1) | EA201890221A1 (enExample) |
| IL (1) | IL256726A (enExample) |
| MX (1) | MX377208B (enExample) |
| WO (1) | WO2017007790A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102651945B1 (ko) | 2015-07-07 | 2024-03-26 | 파이브 일레븐 파마 인크. | Hbed-비스포스포네이트, 이의 방사성금속 접합체 및 이의 진단치료제로서의 용도 |
| WO2018160544A1 (en) * | 2017-03-02 | 2018-09-07 | Five Eleven Pharma Inc. | Radiopharmaceutical labeling device |
| US11723992B2 (en) * | 2018-08-03 | 2023-08-15 | Board Of Regents, The University Of Texas System | Method for extraction and purification of 68GA |
| CN109438517B (zh) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 |
| CN114364405B (zh) * | 2019-04-26 | 2024-07-16 | 五一一制药股份有限公司 | 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂 |
| US20230001027A1 (en) * | 2019-10-01 | 2023-01-05 | City Of Hope | Metal chelating agents and methods of using the same |
| DE102021101216A1 (de) * | 2021-01-21 | 2022-07-21 | Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts | Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen |
| DE102022105175A1 (de) * | 2022-03-04 | 2023-09-07 | Atoms for Cure GmbH | Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik |
| CN119060094B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
| CN119060093B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035114A1 (en) * | 2001-10-22 | 2003-05-01 | Dow Global Technologies Inc. | Radiopharmaceutical agent for the treatment of early stage cancer |
| KR20070087266A (ko) * | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| US7161000B2 (en) * | 2003-05-30 | 2007-01-09 | Sumitomo Chemical Company, Limited | Method for producing phenol condensate |
| US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| EP2921482B1 (en) * | 2007-06-26 | 2018-09-05 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| WO2011021390A1 (ja) * | 2009-08-20 | 2011-02-24 | 富士フイルムＲｉファーマ株式会社 | ビスホスホン酸誘導体及びその放射性金属核種標識体 |
| EP2697347B1 (en) * | 2011-04-13 | 2016-11-16 | Firmenich SA | Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones |
| ITMI20121156A1 (it) | 2012-06-29 | 2013-12-30 | Consiglio Nazionale Ricerche | Metodo di elaborazione di immagini di tomografia a coerenza ottica |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| KR102651945B1 (ko) | 2015-07-07 | 2024-03-26 | 파이브 일레븐 파마 인크. | Hbed-비스포스포네이트, 이의 방사성금속 접합체 및 이의 진단치료제로서의 용도 |
-
2016
- 2016-07-06 KR KR1020187002872A patent/KR102651945B1/ko active Active
- 2016-07-06 CA CA2991498A patent/CA2991498A1/en active Pending
- 2016-07-06 DK DK16821892.3T patent/DK3319643T3/da active
- 2016-07-06 WO PCT/US2016/041040 patent/WO2017007790A1/en not_active Ceased
- 2016-07-06 JP JP2017568376A patent/JP6792875B2/ja active Active
- 2016-07-06 EA EA201890221A patent/EA201890221A1/ru unknown
- 2016-07-06 EP EP16821892.3A patent/EP3319643B1/en active Active
- 2016-07-06 CN CN201680046397.5A patent/CN107847618B/zh active Active
- 2016-07-06 MX MX2018000239A patent/MX377208B/es active IP Right Grant
- 2016-07-06 US US15/203,602 patent/US10253052B2/en active Active
- 2016-07-06 AU AU2016289474A patent/AU2016289474C1/en active Active
-
2018
- 2018-01-03 IL IL256726A patent/IL256726A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524352A5 (enExample) | ||
| JP6977958B2 (ja) | Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤 | |
| EP3397968B1 (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| Ray Banerjee et al. | Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA) | |
| Ray Banerjee et al. | Preclinical comparative study of 68Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA | |
| Shi et al. | Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging | |
| JP6792875B2 (ja) | Ｈｂｅｄ−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 | |
| Rathmann et al. | The radiopharmaceutical chemistry of technetium-99m | |
| Isabel M. Prata | Gallium-68: a new trend in PET radiopharmacy | |
| Imberti et al. | Enhancing PET signal at target tissue in vivo: dendritic and multimeric tris (hydroxypyridinone) conjugates for molecular imaging of αvβ3 integrin expression with gallium-68 | |
| Ferreira et al. | 68Ga small peptide imaging: comparison of NOTA and PCTA | |
| CN109641924B (zh) | 作为检测前列腺特异性膜抗原的过表达的放射性药物的99mtc-edda/hynic-ipsma | |
| CZ20032564A3 (cs) | Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků | |
| Velikyan | Positron emitting [68Ga] Ga-based imaging agents: chemistry and diversity | |
| Chakraborty et al. | Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent | |
| Singh et al. | Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency | |
| Noor et al. | Bivalent inhibitors of prostate-specific membrane antigen conjugated to desferrioxamine B squaramide labeled with zirconium-89 or gallium-68 for diagnostic imaging of prostate cancer | |
| Zhao et al. | Synthesis and evaluation of 68Ga-and 177Lu-labeled (R)-vs (S)-DOTAGA prostate-specific membrane antigen-targeting derivatives | |
| Maresca et al. | Comprehensive radiolabeling, stability, and tissue distribution studies of technetium-99m single amino acid chelates (SAAC) | |
| Shi et al. | 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics | |
| Gomez et al. | Synthesis and Evaluation of Diastereoisomers of 1, 4, 7-Triazacyclononane-1, 4, 7-tris-(glutaric acid)(NOTGA) for Multimeric Radiopharmaceuticals of Gallium | |
| Psimadas et al. | Radiolabeled mAbs as molecular imaging and/or therapy agents targeting PSMA | |
| Liu et al. | Integrin alphavbeta3 directed radiopharmaceuticals for tumor imaging | |
| Bhatt et al. | Phosphonate pendant armed propylene cross-bridged cyclam: synthesis and evaluation as a chelator for Cu-64 | |
| Badipa et al. | An overview of radiolabeled RGD peptides for theranostic applications |